loading
Acadia Pharmaceuticals Inc stock is traded at $16.91, with a volume of 607.16K. It is up +0.81% in the last 24 hours and up +10.49% over the past month. Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
See More
Previous Close:
$16.77
Open:
$16.81
24h Volume:
607.16K
Relative Volume:
0.47
Market Cap:
$2.79B
Revenue:
$890.53M
Net Income/Loss:
$30.57M
P/E Ratio:
-18.38
EPS:
-0.92
Net Cash Flow:
$80.53M
1W Performance:
-7.47%
1M Performance:
+10.49%
6M Performance:
+14.30%
1Y Performance:
-25.98%
1-Day Range:
Value
$16.59
$16.96
1-Week Range:
Value
$16.37
$18.39
52-Week Range:
Value
$14.15
$32.59

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name
Name
Acadia Pharmaceuticals Inc
Name
Phone
858-558-2871
Name
Address
12830 EL CAMINO REAL, SAN DIEGO
Name
Employee
620
Name
Twitter
@acadiapharma
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
ACAD's Discussions on Twitter

Compare ACAD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ACAD 16.90 2.79B 890.53M 30.57M 80.53M -0.92
VRTX 467.02 119.83B 10.63B -479.80M -1.35B 13.33
REGN 759.96 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 564.96 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 231.19 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.53 24.08B 3.30B -501.07M 1.03B 11.54

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-12-24 Downgrade Mizuho Buy → Neutral
Mar-12-24 Reiterated Needham Buy
Jan-30-24 Initiated Robert W. Baird Outperform
Jan-24-24 Upgrade Needham Hold → Buy
Dec-19-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-14-23 Downgrade Deutsche Bank Buy → Hold
Dec-13-23 Initiated Citigroup Buy
Dec-12-23 Initiated Deutsche Bank Buy
Nov-06-23 Upgrade Mizuho Neutral → Buy
Oct-17-23 Initiated UBS Buy
Oct-10-23 Upgrade JP Morgan Neutral → Overweight
Jan-03-23 Upgrade Guggenheim Neutral → Buy
Nov-04-22 Downgrade Goldman Neutral → Sell
Nov-01-22 Initiated Loop Capital Hold
Aug-08-22 Downgrade Citigroup Buy → Neutral
Aug-05-22 Downgrade Citigroup Buy → Neutral
Jun-21-22 Downgrade Jefferies Buy → Underperform
Jun-16-22 Upgrade Jefferies Hold → Buy
Mar-16-22 Upgrade Canaccord Genuity Hold → Buy
Feb-09-22 Upgrade H.C. Wainwright Neutral → Buy
Jan-05-22 Upgrade Citigroup Neutral → Buy
Dec-21-21 Downgrade Guggenheim Buy → Neutral
Nov-01-21 Upgrade Guggenheim Neutral → Buy
Oct-14-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-23-21 Resumed Needham Hold
Jun-10-21 Initiated Berenberg Hold
Apr-07-21 Downgrade H.C. Wainwright Buy → Neutral
Apr-06-21 Downgrade Canaccord Genuity Buy → Hold
Apr-06-21 Downgrade Goldman Buy → Neutral
Apr-06-21 Downgrade Jefferies Buy → Hold
Apr-06-21 Downgrade Mizuho Buy → Neutral
Apr-05-21 Downgrade Raymond James Outperform → Mkt Perform
Mar-10-21 Downgrade BofA Securities Buy → Neutral
Mar-09-21 Downgrade Citigroup Buy → Neutral
Mar-09-21 Downgrade Guggenheim Buy → Neutral
Mar-09-21 Reiterated H.C. Wainwright Buy
Mar-09-21 Downgrade Raymond James Strong Buy → Outperform
Mar-09-21 Downgrade Stifel Buy → Hold
Dec-16-20 Initiated Mizuho Buy
Nov-16-20 Upgrade Raymond James Outperform → Strong Buy
Aug-25-20 Initiated Raymond James Outperform
Aug-20-20 Initiated Morgan Stanley Overweight
Jul-07-20 Upgrade Stifel Hold → Buy
Apr-16-20 Initiated Jefferies Buy
Mar-31-20 Upgrade Goldman Neutral → Buy
Mar-06-20 Initiated Citigroup Buy
Dec-16-19 Initiated Guggenheim Buy
Oct-24-19 Initiated Oppenheimer Perform
Oct-01-19 Initiated RBC Capital Mkts Outperform
Sep-13-19 Upgrade SVB Leerink Mkt Perform → Outperform
Sep-10-19 Upgrade Canaccord Genuity Hold → Buy
Jul-23-19 Reiterated Needham Buy
Dec-10-18 Initiated Canaccord Genuity Hold
Sep-21-18 Upgrade Piper Jaffray Neutral → Overweight
Aug-09-18 Reiterated Stifel Hold
Aug-07-18 Initiated Stifel Hold
Aug-06-18 Downgrade Piper Jaffray Overweight → Neutral
Oct-06-17 Resumed Goldman Neutral
View All

Acadia Pharmaceuticals Inc Stock (ACAD) Latest News

pulisher
Nov 16, 2024

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Sees Large Growth in Short Interest - MarketBeat

Nov 16, 2024
pulisher
Nov 16, 2024

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Holdings Lowered by GSA Capital Partners LLP - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Acadia Pharmaceuticals Grants Stock Options, RSUs to 23 New Employees in Growth Push | ACAD Stock News - StockTitan

Nov 15, 2024
pulisher
Nov 13, 2024

ACADIA Pharmaceuticals' SWOT analysis: mixed results for CNS drug stock By Investing.com - Investing.com Canada

Nov 13, 2024
pulisher
Nov 13, 2024

ACADIA Pharmaceuticals' SWOT analysis: mixed results for CNS drug stock - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $25.56 - MarketBeat

Nov 13, 2024
pulisher
Nov 12, 2024

Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock - Yahoo Finance

Nov 12, 2024
pulisher
Nov 12, 2024

Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth - MSN

Nov 12, 2024
pulisher
Nov 12, 2024

US Bancorp DE Has $507,000 Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Nov 12, 2024
pulisher
Nov 11, 2024

Acadia Pharmaceuticals: Proving The Naysayers Wrong (NASDAQ:ACAD) - Seeking Alpha

Nov 11, 2024
pulisher
Nov 11, 2024

What is Leerink Partnrs' Forecast for ACAD FY2026 Earnings? - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

FY2024 Earnings Estimate for ACAD Issued By HC Wainwright - MarketBeat

Nov 11, 2024
pulisher
Nov 10, 2024

Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates - MSN

Nov 10, 2024
pulisher
Nov 09, 2024

ACADIA Pharmaceuticals Inc. Just Recorded A 43% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance

Nov 09, 2024
pulisher
Nov 08, 2024

Acadia Pharmaceuticals Breaks Above 200-Day Moving AverageBullish for ACAD - Nasdaq

Nov 08, 2024
pulisher
Nov 08, 2024

Acadia Pharmaceuticals price target lowered to $32 from $33 at Canaccord - TipRanks

Nov 08, 2024
pulisher
Nov 08, 2024

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024
pulisher
Nov 08, 2024

Equities Analysts Issue Forecasts for ACAD FY2027 Earnings - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

HC Wainwright Issues Pessimistic Estimate for ACAD Earnings - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - Simply Wall St

Nov 08, 2024
pulisher
Nov 08, 2024

ACADIA Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance

Nov 08, 2024
pulisher
Nov 07, 2024

ACADIA Pharmaceuticals Inc. (ACAD) Quarterly 10-Q Report - Quartzy

Nov 07, 2024
pulisher
Nov 07, 2024

ACADIA Pharmaceuticals (NASDAQ:ACAD) Issues Earnings Results - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Acadia Pharmaceuticals participates in a conference call with JPMorgan - TipRanks

Nov 07, 2024
pulisher
Nov 07, 2024

ACADIA Pharmaceuticals (NASDAQ:ACAD) Given Buy Rating at HC Wainwright - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

ACADIA Pharmaceuticals (NASDAQ:ACAD) Earns Buy Rating from Needham & Company LLC - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Acadia Pharma Q3 2024 Earnings Preview - MSN

Nov 07, 2024
pulisher
Nov 07, 2024

ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... By GuruFocus - Investing.com Canada

Nov 07, 2024
pulisher
Nov 07, 2024

ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highligh - GuruFocus.com

Nov 07, 2024
pulisher
Nov 07, 2024

ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance

Nov 07, 2024
pulisher
Nov 07, 2024

Acadia: Q3 Earnings Snapshot - Houston Chronicle

Nov 07, 2024
pulisher
Nov 07, 2024

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview - BioSpace

Nov 07, 2024
pulisher
Nov 06, 2024

Acadia Pharmaceuticals Sees Revenue Growth and Strategic Advances - TipRanks

Nov 06, 2024
pulisher
Nov 06, 2024

Acadia Pharmaceuticals reports Q3 EPS , consensus 14c - TipRanks

Nov 06, 2024
pulisher
Nov 06, 2024

ACADIA Pharmaceuticals Q3 2024 Earnings: EPS of $0.20 Beats Esti - GuruFocus.com

Nov 06, 2024
pulisher
Nov 06, 2024

Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M - MedCity News

Nov 06, 2024
pulisher
Nov 06, 2024

Acadia Pharma (ACAD) Tops Q3 EPS by 6c ; Offers Guidance - StreetInsider.com

Nov 06, 2024
pulisher
Nov 06, 2024

Acadia Pharma sells priority review voucher for $150 million | Pharmaceutical | The Pharmaletter - The Pharma Letter

Nov 06, 2024
pulisher
Nov 06, 2024

Acadia sells speedy drug review voucher for $150M - BioPharma Dive

Nov 06, 2024
pulisher
Nov 06, 2024

Acadia makes $100M profit from $150M pediatric voucher sale - Fierce Biotech

Nov 06, 2024
pulisher
Nov 06, 2024

Acadia lands $150M sale of rare pediatric PRV - Endpoints News

Nov 06, 2024
pulisher
Nov 06, 2024

Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million - BioSpace

Nov 06, 2024
pulisher
Nov 05, 2024

Acadia Pharmaceuticals to Sell Rare Pediatric Disease Priority Review Voucher - MarketWatch

Nov 05, 2024
pulisher
Nov 05, 2024

Acadia Pharma sells Rare Pediatric Disease Priority Review Voucher for $150M - TipRanks

Nov 05, 2024
pulisher
Nov 05, 2024

Acadia Pharma (ACAD) to Sell Rare Pediatric Disease Priority Review Voucher for $150M - StreetInsider.com

Nov 05, 2024
pulisher
Nov 05, 2024

AlphaCentric Advisors LLC Has $615,000 Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Nov 05, 2024
pulisher
Oct 31, 2024

ACADIA Pharmaceuticals Inc (ACAD): Worst-Performing Growth Stock in 2024 - Insider Monkey

Oct 31, 2024
pulisher
Oct 30, 2024

10 Worst-Performing Growth Stocks in 2024 - Insider Monkey

Oct 30, 2024
pulisher
Oct 30, 2024

Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

Oct 30, 2024
pulisher
Oct 30, 2024

ACADIA Pharmaceuticals (ACAD) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Emerging Insights: Market Trends in Multiple System Atrophy (MSA) Market | Acadia Pharmaceuticals Inc - EIN News

Oct 30, 2024

Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$18.94
price up icon 3.39%
$75.94
price down icon 0.01%
$39.03
price up icon 6.21%
$358.51
price down icon 1.26%
$187.60
price down icon 1.35%
$99.70
price down icon 0.06%
Cap:     |  Volume (24h):